SUBSCRIBE
SUBSCRIBE

GlaxoSmithKline’s Avandia Is Back Under FDA Scrutiny Over Cardiac Risks

July 13, 2010 | 
1 min read
New York Times --
GlaxoSmithKline Food and Drug Administration (FDA)